| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1529-8027.2010.00292.X |
| P698 | PubMed publication ID | 21199103 |
| P50 | author | David R. Cornblath | Q118395409 |
| Ingemar S J Merkies | Q130279190 | ||
| P2093 | author name string | Kathleen A Griffith | |
| Elizabeth E Hill | |||
| P2860 | cites work | Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale | Q44650556 |
| P433 | issue | 4 | |
| P921 | main subject | Chemotherapy-induced peripheral neuropathy | Q17153857 |
| Psychometric Property | Q124708826 | ||
| peripheral neuropathy | Q945238 | ||
| chemotherapy | Q974135 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 314-325 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Journal of the Peripheral Nervous System | Q15764031 |
| P1476 | title | Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties | |
| P478 | volume | 15 |
| Q94487289 | Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review |
| Q35248222 | Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire |
| Q46455283 | CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer |
| Q36770149 | Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy |
| Q50103900 | Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study. |
| Q92233485 | Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials |
| Q41346602 | Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study |
| Q37659699 | Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. |
| Q27010318 | Chemotherapy-induced peripheral neurotoxicity: a critical analysis |
| Q35796623 | Corneal Confocal Microscopy Detects Small Fibre Neuropathy in Patients with Upper Gastrointestinal Cancer and Nerve Regeneration in Chemotherapy Induced Peripheral Neuropathy |
| Q30818191 | Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. |
| Q38254351 | Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. |
| Q90042634 | Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer |
| Q33711656 | Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy |
| Q34336573 | Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial |
| Q48344983 | Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea |
| Q38747276 | Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. |
| Q37273523 | Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment |
| Q47767827 | Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. |
| Q55241487 | In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials. |
| Q37632970 | Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia |
| Q39356105 | Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. |
| Q34458581 | Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer |
| Q36176588 | Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia |
| Q46235962 | Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery. |
| Q47344383 | Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity |
| Q38675106 | Predictive Value of Glycated Hemoglobin and Body Mass Index for Pretreatment Neuropathy in Patients With Multiple Myeloma. |
| Q52591943 | Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures St |
| Q30455590 | Quality of life and measures of quality of life in patients with neuromuscular disorders |
| Q64120952 | Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A15140 |
| Q60678695 | Reply |
| Q47293439 | The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure |
| Q38728572 | Update on Chemotherapy-Induced Peripheral Neuropathy |
| Q28078232 | Vincristine-induced peripheral neuropathy in pediatric cancer patients |
| Q38222174 | What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer |
Search more.